Wedge Capital Management L L P NC Sells 967 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.4% in the fourth quarter, Holdings Channel reports. The fund owned 223,918 shares of the biopharmaceutical company’s stock after selling 967 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Amicus Therapeutics were worth $3,177,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new position in Amicus Therapeutics in the 4th quarter worth approximately $1,173,000. Envestnet Asset Management Inc. boosted its holdings in Amicus Therapeutics by 170.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 393,728 shares of the biopharmaceutical company’s stock worth $4,788,000 after buying an additional 248,220 shares during the period. O Shaughnessy Asset Management LLC boosted its holdings in Amicus Therapeutics by 25.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 3,082 shares during the period. Vanguard Group Inc. boosted its holdings in Amicus Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock worth $329,924,000 after buying an additional 107,456 shares during the period. Finally, MPM Bioimpact LLC boosted its holdings in Amicus Therapeutics by 38.7% in the 3rd quarter. MPM Bioimpact LLC now owns 716,139 shares of the biopharmaceutical company’s stock valued at $8,708,000 after purchasing an additional 200,000 shares during the period.

Amicus Therapeutics Stock Down 1.6 %

FOLD opened at $10.54 on Thursday. The company has a fifty day moving average price of $12.08 and a 200-day moving average price of $12.01. The firm has a market capitalization of $3.11 billion, a P/E ratio of -20.67 and a beta of 0.75. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The company had revenue of $115.08 million for the quarter, compared to the consensus estimate of $115.11 million. Equities research analysts expect that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on FOLD. JPMorgan Chase & Co. reduced their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Insider Transactions at Amicus Therapeutics

In other news, Chairman John F. Crowley sold 31,614 shares of Amicus Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.81, for a total transaction of $436,589.34. Following the completion of the sale, the chairman now directly owns 697,628 shares of the company’s stock, valued at approximately $9,634,242.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Amicus Therapeutics news, Chairman John F. Crowley sold 31,614 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.81, for a total value of $436,589.34. Following the completion of the sale, the chairman now directly owns 697,628 shares of the company’s stock, valued at $9,634,242.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Margaret G. Mcglynn sold 7,500 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total transaction of $100,500.00. Following the completion of the sale, the director now directly owns 59,289 shares of the company’s stock, valued at $794,472.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,108 shares of company stock valued at $662,605. Insiders own 2.10% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.